Trial Outcomes & Findings for A Study to Evaluate the Safety and Immunogenicity of V710 in Adults With Kidney Disease on Hemodialysis (V710-005)(COMPLETED) (NCT NCT00572910)
NCT ID: NCT00572910
Last Updated: 2015-04-03
Results Overview
Participants whose GMFR in anti-0657n IgG antibody concentration was measured by the LUMINEX™ assay from Baseline to 28 days after the administration of the second vaccination of V710 for the 3 groups receiving 2 doses of V710 (60 mcg without MAA) Group 1, (60 mcg with MAA) Group 3 and (90 mcg with MAA) Group 5.
Recruitment status
COMPLETED
Study phase
PHASE2
Target enrollment
206 participants
Primary outcome timeframe
Prevaccination to 56 days postvaccination
Results posted on
2015-04-03
Participant Flow
Participant milestones
| Measure |
V710 (60 mcg / 60 mcg / 60 mcg)
Participants in Group 1A who were vaccinated with V710 (60 mcg / 60 mcg / 60 mcg) without MAA.
|
V710 (60 mcg / 60 mcg / PBO)
Participants in Group 1B who were vaccinated with V710 (60 mcg / 60 mcg / PBO) without MAA.
|
V710 (60 mcg / PBO / 60 mcg)
Participants in Group 2A who were vaccinated with V710 (60 mcg / PBO / 60 mcg) without MAA.
|
V710 (60 mcg / PBO / PBO)
Participants in Group 2B who were vaccinated with V710 (60 mcg / PBO / PBO) without MAA.
|
V710 (60 mcg / 60 mcg / 60 mcg) + MAA
Participants in Group 3A who were vaccinated with V710 (60 mcg / 60 mcg / 60 mcg) with MAA.
|
V710 (60 mcg / 60 mcg / PBO) + MAA
Participants in Group 3B who were vaccinated with V710 (60 mcg / 60 mcg /PBO) with MAA.
|
V710 (60 mcg / PBO / 60 mcg) + MAA
Participants in Group 4A who were vaccinated with V710 (60 mcg / PBO / 60 mcg) with MAA.
|
V710 (60 mcg / PBO / PBO) + MAA
Participants in Group 4B who were vaccinated with V710 (60 mcg / PBO / PBO) with MAA.
|
V710 (90 mcg / 90 mcg / 90 mcg) + MAA
Participants in Group 5A who were vaccinated with V710 (90 mcg / 90 mcg / 90 mcg) with MAA.
|
V710 (90 mcg / 90 mcg / PBO) + MAA
Participants in Group 5B who were vaccinated with V710 (90 mcg / 90 mcg / PBO) with MAA.
|
Placebo (PBO / PBO / PBO)
Participants in Group 6 who were vaccinated with Placebo (PBO / PBO / PBO).
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Study
STARTED
|
19
|
18
|
19
|
18
|
19
|
19
|
19
|
19
|
19
|
19
|
18
|
|
Overall Study
COMPLETED
|
15
|
15
|
17
|
14
|
17
|
16
|
15
|
15
|
16
|
13
|
15
|
|
Overall Study
NOT COMPLETED
|
4
|
3
|
2
|
4
|
2
|
3
|
4
|
4
|
3
|
6
|
3
|
Reasons for withdrawal
| Measure |
V710 (60 mcg / 60 mcg / 60 mcg)
Participants in Group 1A who were vaccinated with V710 (60 mcg / 60 mcg / 60 mcg) without MAA.
|
V710 (60 mcg / 60 mcg / PBO)
Participants in Group 1B who were vaccinated with V710 (60 mcg / 60 mcg / PBO) without MAA.
|
V710 (60 mcg / PBO / 60 mcg)
Participants in Group 2A who were vaccinated with V710 (60 mcg / PBO / 60 mcg) without MAA.
|
V710 (60 mcg / PBO / PBO)
Participants in Group 2B who were vaccinated with V710 (60 mcg / PBO / PBO) without MAA.
|
V710 (60 mcg / 60 mcg / 60 mcg) + MAA
Participants in Group 3A who were vaccinated with V710 (60 mcg / 60 mcg / 60 mcg) with MAA.
|
V710 (60 mcg / 60 mcg / PBO) + MAA
Participants in Group 3B who were vaccinated with V710 (60 mcg / 60 mcg /PBO) with MAA.
|
V710 (60 mcg / PBO / 60 mcg) + MAA
Participants in Group 4A who were vaccinated with V710 (60 mcg / PBO / 60 mcg) with MAA.
|
V710 (60 mcg / PBO / PBO) + MAA
Participants in Group 4B who were vaccinated with V710 (60 mcg / PBO / PBO) with MAA.
|
V710 (90 mcg / 90 mcg / 90 mcg) + MAA
Participants in Group 5A who were vaccinated with V710 (90 mcg / 90 mcg / 90 mcg) with MAA.
|
V710 (90 mcg / 90 mcg / PBO) + MAA
Participants in Group 5B who were vaccinated with V710 (90 mcg / 90 mcg / PBO) with MAA.
|
Placebo (PBO / PBO / PBO)
Participants in Group 6 who were vaccinated with Placebo (PBO / PBO / PBO).
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Study
Adverse Event
|
1
|
2
|
0
|
2
|
0
|
0
|
4
|
2
|
1
|
3
|
2
|
|
Overall Study
Lost to Follow-up
|
0
|
1
|
1
|
2
|
1
|
0
|
0
|
0
|
0
|
1
|
0
|
|
Overall Study
Withdrawal by Subject
|
3
|
0
|
1
|
0
|
1
|
3
|
0
|
2
|
2
|
2
|
1
|
Baseline Characteristics
A Study to Evaluate the Safety and Immunogenicity of V710 in Adults With Kidney Disease on Hemodialysis (V710-005)(COMPLETED)
Baseline characteristics by cohort
| Measure |
V710 (60 mcg / 60 mcg)
n=37 Participants
Participants who were vaccinated with V710 (60 mcg without MAA) on Day 1 and Day 28.
|
V710 (60 mcg / PBO)
n=37 Participants
Participants who were vaccinated with V710 (60 mcg without MAA) on Day 1 and Placebo on Day 28.
|
V710 (60 mcg / 60 mcg) + MAA
n=38 Participants
Participants who were vaccinated with V710 (60 mcg with MAA) on Day 1 and Day 28.
|
V710 (60 mcg / PBO) + MAA
n=38 Participants
Participants who were vaccinated with V710 (60 mcg with MAA) on Day 1 and Placebo on Day 28.
|
V710 (90 mcg / 90 mcg) + MAA
n=38 Participants
Participants who were vaccinated with V710 (90 mcg with MAA) on Day 1 and Day 28.
|
Placebo (PBO / PBO)
n=18 Participants
Participants who were vaccinated with Placebo on Day 1 and Day 28.
|
Total
n=206 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|
|
Age, Customized
<50 years of age
|
10 Participants
n=5 Participants
|
14 Participants
n=7 Participants
|
14 Participants
n=5 Participants
|
5 Participants
n=4 Participants
|
14 Participants
n=21 Participants
|
6 Participants
n=10 Participants
|
63 Participants
n=115 Participants
|
|
Age, Customized
>=50 years of age
|
27 Participants
n=5 Participants
|
23 Participants
n=7 Participants
|
24 Participants
n=5 Participants
|
33 Participants
n=4 Participants
|
24 Participants
n=21 Participants
|
12 Participants
n=10 Participants
|
143 Participants
n=115 Participants
|
|
Sex: Female, Male
Female
|
13 Participants
n=5 Participants
|
15 Participants
n=7 Participants
|
19 Participants
n=5 Participants
|
14 Participants
n=4 Participants
|
16 Participants
n=21 Participants
|
7 Participants
n=10 Participants
|
84 Participants
n=115 Participants
|
|
Sex: Female, Male
Male
|
24 Participants
n=5 Participants
|
22 Participants
n=7 Participants
|
19 Participants
n=5 Participants
|
24 Participants
n=4 Participants
|
22 Participants
n=21 Participants
|
11 Participants
n=10 Participants
|
122 Participants
n=115 Participants
|
PRIMARY outcome
Timeframe: Prevaccination to 56 days postvaccinationParticipants whose GMFR in anti-0657n IgG antibody concentration was measured by the LUMINEX™ assay from Baseline to 28 days after the administration of the second vaccination of V710 for the 3 groups receiving 2 doses of V710 (60 mcg without MAA) Group 1, (60 mcg with MAA) Group 3 and (90 mcg with MAA) Group 5.
Outcome measures
| Measure |
V710 (60 mcg Without MAA) - Group 1
n=36 Participants
Participants in Group 1 were vaccinated with V710 (60 mcg without MAA) on Day 1 and Day 28.
|
V710 (60 mcg With MAA) - Group 3
n=37 Participants
Participants in Group 3 were vaccinated with V710 (60 mcg with MAA) on Day 1 and Day 28.
|
V710 (90 mcg With MAA) - Group 5
n=36 Participants
Participants in Group 5 were vaccinated with V710 (90 mcg with MAA) on Day 1 and Day 28.
|
V710 (60 mcg / PBO / PBO)
Participants in Group 2B who were vaccinated with V710 (60 mcg / PBO / PBO) without MAA.
|
V710 (60 mcg / 60 mcg / 60 mcg) + MAA
Participants in Group 3A who were vaccinated with V710 (60 mcg / 60 mcg / 60 mcg) with MAA.
|
V710 (60 mcg / 60 mcg / PBO) + MAA
Participants in Group 3B who were vaccinated with V710 (60 mcg / 60 mcg / PBO) with MAA.
|
V710 (60 mcg / PBO / 60 mcg) + MAA
Participants in Group 4A who were vaccinated with V710 (60 mcg / PBO / 60 mcg) with MAA.
|
V710 (60 mcg / PBO / PBO) + MAA
Participants in Group 4B who were vaccinated with V710 (60 mcg / PBO / PBO) with MAA.
|
V710 (90 mcg / 90 mcg / 90 mcg) + MAA
Participants in Group 5A who were vaccinated with V710 (90 mcg / 90 mcg / 90 mcg) with MAA.
|
V710 (90 mcg / 90 mcg / PBO) + MAA
Participants in Group 5B who were vaccinated with V710 (90 mcg / 90 mcg / PBO) with MAA.
|
Placebo (PBO / PBO / PBO)
Participants in Group 6 who were vaccinated with Placebo (PBO / PBO / PBO).
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Geometric Mean Fold-rise (GMFR) in 0657n-specific Immunoglobulin G (IgG) Antibody Concentration From Baseline to 28 Days After the Administration of the Second V710 Vaccination
|
18.9 Ratio
Interval 13.7 to 26.1
|
15.1 Ratio
Interval 11.0 to 20.8
|
17.8 Ratio
Interval 13.0 to 24.3
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Days 1-14 following each vaccination for any AE/SAE and Days 1-360 for any vaccine-related SAEs, S. aureus SAEs, or deaths.Participants with Adverse Experiences (AE) / Serious Adverse Experiences (SAE) occurring Day 1 through Day 14 following vaccinations 1, 2, and 3. Participants with specific SAEs including any vaccine-related SAEs, any SAEs involving a Staphylococcus aureus (S. aureus) infection, or any AEs leading to death occurring Day 1 through Day 360 following vaccination.
Outcome measures
| Measure |
V710 (60 mcg Without MAA) - Group 1
n=18 Participants
Participants in Group 1 were vaccinated with V710 (60 mcg without MAA) on Day 1 and Day 28.
|
V710 (60 mcg With MAA) - Group 3
n=18 Participants
Participants in Group 3 were vaccinated with V710 (60 mcg with MAA) on Day 1 and Day 28.
|
V710 (90 mcg With MAA) - Group 5
n=19 Participants
Participants in Group 5 were vaccinated with V710 (90 mcg with MAA) on Day 1 and Day 28.
|
V710 (60 mcg / PBO / PBO)
n=18 Participants
Participants in Group 2B who were vaccinated with V710 (60 mcg / PBO / PBO) without MAA.
|
V710 (60 mcg / 60 mcg / 60 mcg) + MAA
n=19 Participants
Participants in Group 3A who were vaccinated with V710 (60 mcg / 60 mcg / 60 mcg) with MAA.
|
V710 (60 mcg / 60 mcg / PBO) + MAA
n=18 Participants
Participants in Group 3B who were vaccinated with V710 (60 mcg / 60 mcg / PBO) with MAA.
|
V710 (60 mcg / PBO / 60 mcg) + MAA
n=19 Participants
Participants in Group 4A who were vaccinated with V710 (60 mcg / PBO / 60 mcg) with MAA.
|
V710 (60 mcg / PBO / PBO) + MAA
n=18 Participants
Participants in Group 4B who were vaccinated with V710 (60 mcg / PBO / PBO) with MAA.
|
V710 (90 mcg / 90 mcg / 90 mcg) + MAA
n=17 Participants
Participants in Group 5A who were vaccinated with V710 (90 mcg / 90 mcg / 90 mcg) with MAA.
|
V710 (90 mcg / 90 mcg / PBO) + MAA
n=19 Participants
Participants in Group 5B who were vaccinated with V710 (90 mcg / 90 mcg / PBO) with MAA.
|
Placebo (PBO / PBO / PBO)
n=18 Participants
Participants in Group 6 who were vaccinated with Placebo (PBO / PBO / PBO).
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants With Adverse Experiences (AE)/Serious Adverse Experiences (SAE)
Participants with any AE's (Day 1 - 14)
|
8 Participants
|
9 Participants
|
5 Participants
|
6 Participants
|
9 Participants
|
11 Participants
|
10 Participants
|
9 Participants
|
10 Participants
|
10 Participants
|
7 Participants
|
|
Number of Participants With Adverse Experiences (AE)/Serious Adverse Experiences (SAE)
Participants with any SAE's (Day 1 - 14)
|
1 Participants
|
1 Participants
|
0 Participants
|
2 Participants
|
0 Participants
|
4 Participants
|
0 Participants
|
1 Participants
|
2 Participants
|
1 Participants
|
0 Participants
|
|
Number of Participants With Adverse Experiences (AE)/Serious Adverse Experiences (SAE)
Any vaccine-related SAE's (Day 1 - 360)
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Adverse Experiences (AE)/Serious Adverse Experiences (SAE)
Any SAE's with S. aureus infection (Day 1 - 360)
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
2 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
|
Number of Participants With Adverse Experiences (AE)/Serious Adverse Experiences (SAE)
Any AE's involving Death (Day 1 - 360)
|
1 Participants
|
2 Participants
|
0 Participants
|
2 Participants
|
0 Participants
|
0 Participants
|
4 Participants
|
1 Participants
|
1 Participants
|
3 Participants
|
2 Participants
|
SECONDARY outcome
Timeframe: Prevaccination to 28 days postvaccinationParticipants whose GMFR in anti-0657n IgG antibody concentration was measured from Baseline to Day 28 for the 3 Groups receiving 1 dose of V710 (60 mcg without MAA) Group 1 and 2 combined, (60 mcg with MAA) Group 3 and 4 combined and (90 mcg with MAA) Group 5.
Outcome measures
| Measure |
V710 (60 mcg Without MAA) - Group 1
n=73 Participants
Participants in Group 1 were vaccinated with V710 (60 mcg without MAA) on Day 1 and Day 28.
|
V710 (60 mcg With MAA) - Group 3
n=74 Participants
Participants in Group 3 were vaccinated with V710 (60 mcg with MAA) on Day 1 and Day 28.
|
V710 (90 mcg With MAA) - Group 5
n=36 Participants
Participants in Group 5 were vaccinated with V710 (90 mcg with MAA) on Day 1 and Day 28.
|
V710 (60 mcg / PBO / PBO)
Participants in Group 2B who were vaccinated with V710 (60 mcg / PBO / PBO) without MAA.
|
V710 (60 mcg / 60 mcg / 60 mcg) + MAA
Participants in Group 3A who were vaccinated with V710 (60 mcg / 60 mcg / 60 mcg) with MAA.
|
V710 (60 mcg / 60 mcg / PBO) + MAA
Participants in Group 3B who were vaccinated with V710 (60 mcg / 60 mcg / PBO) with MAA.
|
V710 (60 mcg / PBO / 60 mcg) + MAA
Participants in Group 4A who were vaccinated with V710 (60 mcg / PBO / 60 mcg) with MAA.
|
V710 (60 mcg / PBO / PBO) + MAA
Participants in Group 4B who were vaccinated with V710 (60 mcg / PBO / PBO) with MAA.
|
V710 (90 mcg / 90 mcg / 90 mcg) + MAA
Participants in Group 5A who were vaccinated with V710 (90 mcg / 90 mcg / 90 mcg) with MAA.
|
V710 (90 mcg / 90 mcg / PBO) + MAA
Participants in Group 5B who were vaccinated with V710 (90 mcg / 90 mcg / PBO) with MAA.
|
Placebo (PBO / PBO / PBO)
Participants in Group 6 who were vaccinated with Placebo (PBO / PBO / PBO).
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
GMFR in 0657n-specific IgG Antibody Concentration From Baseline to Day 28 After the Administration of the First V710 Vaccination
|
11.9 Ratio
95% Confidence Interval 9.0 • Interval 9.0 to 15.6
|
12.9 Ratio
95% Confidence Interval 12.9 • Interval 9.8 to 16.9
|
12.9 Ratio
Interval 8.8 to 18.8
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Prevaccination to 180 days postvaccinationParticipants whose GMFR in anti-0657n IgG antibody concentration was measured from Baseline to Day 180 for the 3 Groups receiving 2 doses of V710 28 days apart (60 mcg without MAA) Group 1, (60 mcg with MAA) Group 3 and (90 mcg with MAA) Group 5.
Outcome measures
| Measure |
V710 (60 mcg Without MAA) - Group 1
n=36 Participants
Participants in Group 1 were vaccinated with V710 (60 mcg without MAA) on Day 1 and Day 28.
|
V710 (60 mcg With MAA) - Group 3
n=37 Participants
Participants in Group 3 were vaccinated with V710 (60 mcg with MAA) on Day 1 and Day 28.
|
V710 (90 mcg With MAA) - Group 5
n=36 Participants
Participants in Group 5 were vaccinated with V710 (90 mcg with MAA) on Day 1 and Day 28.
|
V710 (60 mcg / PBO / PBO)
Participants in Group 2B who were vaccinated with V710 (60 mcg / PBO / PBO) without MAA.
|
V710 (60 mcg / 60 mcg / 60 mcg) + MAA
Participants in Group 3A who were vaccinated with V710 (60 mcg / 60 mcg / 60 mcg) with MAA.
|
V710 (60 mcg / 60 mcg / PBO) + MAA
Participants in Group 3B who were vaccinated with V710 (60 mcg / 60 mcg / PBO) with MAA.
|
V710 (60 mcg / PBO / 60 mcg) + MAA
Participants in Group 4A who were vaccinated with V710 (60 mcg / PBO / 60 mcg) with MAA.
|
V710 (60 mcg / PBO / PBO) + MAA
Participants in Group 4B who were vaccinated with V710 (60 mcg / PBO / PBO) with MAA.
|
V710 (90 mcg / 90 mcg / 90 mcg) + MAA
Participants in Group 5A who were vaccinated with V710 (90 mcg / 90 mcg / 90 mcg) with MAA.
|
V710 (90 mcg / 90 mcg / PBO) + MAA
Participants in Group 5B who were vaccinated with V710 (90 mcg / 90 mcg / PBO) with MAA.
|
Placebo (PBO / PBO / PBO)
Participants in Group 6 who were vaccinated with Placebo (PBO / PBO / PBO).
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
GMFR in 0657n-specific IgG Antibody Concentration From Baseline to Day 180 After the Administration of the First V710 Vaccination
|
8.5 Ratio
Interval 6.2 to 11.8
|
5.7 Ratio
Interval 4.2 to 7.9
|
7.6 Ratio
Interval 5.5 to 10.6
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Prevaccination to 56 days postvaccinationParticipants whose GMFR in 0657n-specific IgG antibody concentration from Baseline to Day 56 for the 2 Groups receiving a single dose of V710 (60 mcg without MAA followed by Placebo 28 Days later) Group 2, and (60 mcg with MAA followed by Placebo 28 days later) Group 4.
Outcome measures
| Measure |
V710 (60 mcg Without MAA) - Group 1
n=37 Participants
Participants in Group 1 were vaccinated with V710 (60 mcg without MAA) on Day 1 and Day 28.
|
V710 (60 mcg With MAA) - Group 3
n=37 Participants
Participants in Group 3 were vaccinated with V710 (60 mcg with MAA) on Day 1 and Day 28.
|
V710 (90 mcg With MAA) - Group 5
Participants in Group 5 were vaccinated with V710 (90 mcg with MAA) on Day 1 and Day 28.
|
V710 (60 mcg / PBO / PBO)
Participants in Group 2B who were vaccinated with V710 (60 mcg / PBO / PBO) without MAA.
|
V710 (60 mcg / 60 mcg / 60 mcg) + MAA
Participants in Group 3A who were vaccinated with V710 (60 mcg / 60 mcg / 60 mcg) with MAA.
|
V710 (60 mcg / 60 mcg / PBO) + MAA
Participants in Group 3B who were vaccinated with V710 (60 mcg / 60 mcg / PBO) with MAA.
|
V710 (60 mcg / PBO / 60 mcg) + MAA
Participants in Group 4A who were vaccinated with V710 (60 mcg / PBO / 60 mcg) with MAA.
|
V710 (60 mcg / PBO / PBO) + MAA
Participants in Group 4B who were vaccinated with V710 (60 mcg / PBO / PBO) with MAA.
|
V710 (90 mcg / 90 mcg / 90 mcg) + MAA
Participants in Group 5A who were vaccinated with V710 (90 mcg / 90 mcg / 90 mcg) with MAA.
|
V710 (90 mcg / 90 mcg / PBO) + MAA
Participants in Group 5B who were vaccinated with V710 (90 mcg / 90 mcg / PBO) with MAA.
|
Placebo (PBO / PBO / PBO)
Participants in Group 6 who were vaccinated with Placebo (PBO / PBO / PBO).
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
GMFR in 0657n-specific IgG Antibody Concentration From Baseline to 56 Days After the Administration of a Single V710 Vaccination
|
9.6 Ratio
Interval 7.1 to 13.1
|
11.8 Ratio
Interval 8.6 to 16.1
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Prevaccination to 360 days post vaccinationParticipants whose GMFR in 0657n-specific IgG antibody concentration from baseline through Day 360 for all groups (including Days 28, 56, 84,180, 210, 270, and 360) to assess the durability and kinetics of the immune response.
Outcome measures
| Measure |
V710 (60 mcg Without MAA) - Group 1
n=18 Participants
Participants in Group 1 were vaccinated with V710 (60 mcg without MAA) on Day 1 and Day 28.
|
V710 (60 mcg With MAA) - Group 3
n=18 Participants
Participants in Group 3 were vaccinated with V710 (60 mcg with MAA) on Day 1 and Day 28.
|
V710 (90 mcg With MAA) - Group 5
n=19 Participants
Participants in Group 5 were vaccinated with V710 (90 mcg with MAA) on Day 1 and Day 28.
|
V710 (60 mcg / PBO / PBO)
n=18 Participants
Participants in Group 2B who were vaccinated with V710 (60 mcg / PBO / PBO) without MAA.
|
V710 (60 mcg / 60 mcg / 60 mcg) + MAA
n=19 Participants
Participants in Group 3A who were vaccinated with V710 (60 mcg / 60 mcg / 60 mcg) with MAA.
|
V710 (60 mcg / 60 mcg / PBO) + MAA
n=18 Participants
Participants in Group 3B who were vaccinated with V710 (60 mcg / 60 mcg / PBO) with MAA.
|
V710 (60 mcg / PBO / 60 mcg) + MAA
n=19 Participants
Participants in Group 4A who were vaccinated with V710 (60 mcg / PBO / 60 mcg) with MAA.
|
V710 (60 mcg / PBO / PBO) + MAA
n=18 Participants
Participants in Group 4B who were vaccinated with V710 (60 mcg / PBO / PBO) with MAA.
|
V710 (90 mcg / 90 mcg / 90 mcg) + MAA
n=17 Participants
Participants in Group 5A who were vaccinated with V710 (90 mcg / 90 mcg / 90 mcg) with MAA.
|
V710 (90 mcg / 90 mcg / PBO) + MAA
n=19 Participants
Participants in Group 5B who were vaccinated with V710 (90 mcg / 90 mcg / PBO) with MAA.
|
Placebo (PBO / PBO / PBO)
n=18 Participants
Participants in Group 6 who were vaccinated with Placebo (PBO / PBO / PBO).
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
GMFR in 0657n-specific IgG Antibody Concentration From Baseline as Measured at 8 Predefined Timepoints
Day 28
|
19.4 Ratio
Interval 8.0 to 47.0
|
13.4 Ratio
Interval 8.2 to 21.9
|
9.2 Ratio
Interval 5.1 to 16.6
|
9.8 Ratio
Interval 5.1 to 18.5
|
11.7 Ratio
Interval 6.5 to 21.2
|
10.8 Ratio
Interval 6.0 to 19.6
|
11.4 Ratio
Interval 6.0 to 22.0
|
14.4 Ratio
Interval 9.6 to 21.6
|
16.3 Ratio
Interval 9.2 to 28.8
|
11.4 Ratio
Interval 5.7 to 22.8
|
1.2 Ratio
Interval 0.9 to 1.5
|
|
GMFR in 0657n-specific IgG Antibody Concentration From Baseline as Measured at 8 Predefined Timepoints
Day 56
|
30.3 Ratio
Interval 17.7 to 51.9
|
14.6 Ratio
Interval 8.6 to 24.8
|
10.3 Ratio
Interval 5.9 to 18.0
|
7.8 Ratio
Interval 4.5 to 13.4
|
17.3 Ratio
Interval 10.6 to 28.3
|
12.8 Ratio
Interval 8.4 to 19.5
|
9.1 Ratio
Interval 5.3 to 15.6
|
13.1 Ratio
Interval 8.6 to 20.1
|
19.5 Ratio
Interval 11.7 to 32.6
|
17.5 Ratio
Interval 9.0 to 34.0
|
1.1 Ratio
Interval 0.9 to 1.4
|
|
GMFR in 0657n-specific IgG Antibody Concentration From Baseline as Measured at 8 Predefined Timepoints
Day 84
|
26.5 Ratio
Interval 16.2 to 43.3
|
12.1 Ratio
Interval 7.1 to 20.5
|
7.8 Ratio
Interval 4.6 to 13.1
|
6.9 Ratio
Interval 3.8 to 12.6
|
13.7 Ratio
Interval 8.7 to 21.5
|
13.0 Ratio
Interval 8.3 to 20.4
|
7.7 Ratio
Interval 4.1 to 14.3
|
10.0 Ratio
Interval 6.1 to 16.2
|
18.8 Ratio
Interval 11.4 to 30.7
|
17.2 Ratio
Interval 8.7 to 33.9
|
1.6 Ratio
Interval 0.8 to 3.0
|
|
GMFR in 0657n-specific IgG Antibody Concentration From Baseline as Measured at 8 Predefined Timepoints
Day 210
|
13.6 Ratio
Interval 7.8 to 23.8
|
5.6 Ratio
Interval 3.4 to 9.3
|
7.0 Ratio
Interval 4.4 to 11.0
|
4.1 Ratio
Interval 2.2 to 7.5
|
10.1 Ratio
Interval 6.3 to 16.1
|
5.4 Ratio
Interval 3.4 to 8.5
|
6.1 Ratio
Interval 4.0 to 9.2
|
4.4 Ratio
Interval 2.6 to 7.4
|
11.3 Ratio
Interval 6.6 to 19.4
|
7.7 Ratio
Interval 4.4 to 13.6
|
1.1 Ratio
Interval 0.9 to 1.3
|
|
GMFR in 0657n-specific IgG Antibody Concentration From Baseline as Measured at 8 Predefined Timepoints
Day 270
|
8.7 Ratio
Interval 5.5 to 13.6
|
4.0 Ratio
Interval 2.6 to 6.1
|
5.5 Ratio
Interval 3.5 to 8.7
|
3.6 Ratio
Interval 2.0 to 6.4
|
8.2 Ratio
Interval 5.2 to 12.8
|
3.7 Ratio
Interval 2.3 to 6.0
|
5.3 Ratio
Interval 3.6 to 7.9
|
3.9 Ratio
Interval 2.5 to 6.3
|
10.7 Ratio
Interval 5.8 to 19.9
|
5.8 Ratio
Interval 2.9 to 11.6
|
0.9 Ratio
Interval 0.5 to 1.7
|
|
GMFR in 0657n-specific IgG Antibody Concentration From Baseline as Measured at 8 Predefined Timepoints
Day 360
|
5.9 Ratio
Interval 3.9 to 8.8
|
3.4 Ratio
Interval 1.8 to 6.3
|
3.9 Ratio
Interval 2.6 to 5.8
|
3.5 Ratio
Interval 1.7 to 7.2
|
4.6 Ratio
Interval 2.6 to 8.2
|
2.9 Ratio
Interval 1.9 to 4.4
|
3.5 Ratio
Interval 2.3 to 5.2
|
3.1 Ratio
Interval 1.9 to 4.9
|
6.6 Ratio
Interval 4.0 to 11.0
|
5.2 Ratio
Interval 2.9 to 9.4
|
1.5 Ratio
Interval 0.9 to 2.4
|
|
GMFR in 0657n-specific IgG Antibody Concentration From Baseline as Measured at 8 Predefined Timepoints
Day 1
|
22.2 Ratio
Interval 13.6 to 36.4
|
19.9 Ratio
Interval 11.7 to 34.1
|
36.3 Ratio
Interval 24.3 to 54.0
|
24.6 Ratio
Interval 14.1 to 42.8
|
26.9 Ratio
Interval 16.6 to 43.8
|
33.7 Ratio
Interval 20.1 to 56.8
|
36.6 Ratio
Interval 23.6 to 56.7
|
26.6 Ratio
Interval 16.9 to 41.9
|
24.4 Ratio
Interval 15.1 to 39.3
|
25.4 Ratio
Interval 17.4 to 37.1
|
30.2 Ratio
Interval 20.7 to 44.0
|
|
GMFR in 0657n-specific IgG Antibody Concentration From Baseline as Measured at 8 Predefined Timepoints
Day 180
|
13.0 Ratio
Interval 7.5 to 22.6
|
7.3 Ratio
Interval 4.9 to 11.1
|
4.0 Ratio
Interval 2.4 to 6.5
|
4.2 Ratio
Interval 2.6 to 6.7
|
5.7 Ratio
Interval 2.7 to 11.9
|
5.8 Ratio
Interval 3.7 to 8.9
|
3.7 Ratio
Interval 2.3 to 6.0
|
5.5 Ratio
Interval 3.2 to 9.4
|
8.5 Ratio
Interval 5.1 to 14.1
|
10.1 Ratio
Interval 5.5 to 18.6
|
1.0 Ratio
Interval 0.8 to 1.3
|
Adverse Events
V710 (60 mcg / 60 mcg / 60 mcg)
Serious events: 2 serious events
Other events: 8 other events
Deaths: 0 deaths
V710 (60 mcg / 60 mcg / PBO)
Serious events: 3 serious events
Other events: 9 other events
Deaths: 0 deaths
V710 (60 mcg / PBO / 60 mcg)
Serious events: 2 serious events
Other events: 5 other events
Deaths: 0 deaths
V710 (60 mcg / PBO / PBO)
Serious events: 5 serious events
Other events: 4 other events
Deaths: 0 deaths
V710 (60 mcg / 60 mcg / 60 mcg) + MAA
Serious events: 0 serious events
Other events: 9 other events
Deaths: 0 deaths
V710 (60 mcg / 60 mcg / PBO) + MAA
Serious events: 5 serious events
Other events: 10 other events
Deaths: 0 deaths
V710 (60 mcg / PBO / 60 mcg) + MAA
Serious events: 4 serious events
Other events: 10 other events
Deaths: 0 deaths
V710 (60 mcg / PBO / PBO) + MAA
Serious events: 2 serious events
Other events: 8 other events
Deaths: 0 deaths
V710 (90 mcg / 90 mcg / 90 mcg) + MAA
Serious events: 2 serious events
Other events: 9 other events
Deaths: 0 deaths
V710 (90 mcg / 90 mcg / PBO) + MAA
Serious events: 5 serious events
Other events: 10 other events
Deaths: 0 deaths
Placebo (PBO / PBO / PBO)
Serious events: 3 serious events
Other events: 7 other events
Deaths: 0 deaths
Serious adverse events
| Measure |
V710 (60 mcg / 60 mcg / 60 mcg)
n=18 participants at risk
Participants in Group 1A who were vaccinated with V710 (60 mcg / 60 mcg / 60 mcg) without MAA.
|
V710 (60 mcg / 60 mcg / PBO)
n=18 participants at risk
Participants in Group 1B who were vaccinated with V710 (60 mcg / 60 mcg / PBO) without MAA.
|
V710 (60 mcg / PBO / 60 mcg)
n=19 participants at risk
Participants in Group 2A who were vaccinated with V710 (60 mcg / PBO / 60 mcg) without MAA.
|
V710 (60 mcg / PBO / PBO)
n=18 participants at risk
Participants in Group 2B who were vaccinated with V710 (60 mcg / PBO / PBO) without MAA.
|
V710 (60 mcg / 60 mcg / 60 mcg) + MAA
n=19 participants at risk
Participants in Group 3A who were vaccinated with V710 (60 mcg / 60 mcg / 60 mcg) with MAA.
|
V710 (60 mcg / 60 mcg / PBO) + MAA
n=18 participants at risk
Participants in Group 3B who were vaccinated with V710 (60 mcg / 60 mcg / PBO) with MAA.
|
V710 (60 mcg / PBO / 60 mcg) + MAA
n=19 participants at risk
Participants in Group 4A who were vaccinated with V710 (60 mcg / PBO / PBO) with MAA.
|
V710 (60 mcg / PBO / PBO) + MAA
n=18 participants at risk
Participants in Group 4B who were vaccinated with V710 (60 mcg / PBO / PBO) with MAA.
|
V710 (90 mcg / 90 mcg / 90 mcg) + MAA
n=17 participants at risk
Participants in Group 5A who were vaccinated with V710 (90 mcg / 90 mcg / 90 mcg) with MAA.
|
V710 (90 mcg / 90 mcg / PBO) + MAA
n=19 participants at risk
Participants in Group 5B who were vaccinated with V710 (90 mcg / 90 mcg / PBO) with MAA.
|
Placebo (PBO / PBO / PBO)
n=18 participants at risk
Participants in Group 6 who were vaccinated with Placebo (PBO / PBO / PBO).
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Injury, poisoning and procedural complications
Joint injury
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Metabolism and nutrition disorders
Diabetic ketoacidosis
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Metabolism and nutrition disorders
Fluid overload
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.9%
1/17 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.9%
1/17 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Metabolism and nutrition disorders
Hypoglycaemia
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.9%
1/17 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Metabolism and nutrition disorders
Lactic acidosis
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.9%
1/17 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast cancer
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Nervous system disorders
Petit mal epilepsy
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Renal and urinary disorders
Azotaemia
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Respiratory, thoracic and mediastinal disorders
Chronic obstructive pulmonary disease
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.9%
1/17 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary oedema
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory failure
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.9%
1/17 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Vascular disorders
Aortic dissection
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Vascular disorders
Jugular vein thrombosis
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Vascular disorders
Shock
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.9%
1/17 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Vascular disorders
Thrombosis
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Vascular disorders
Vena cava thrombosis
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Blood and lymphatic system disorders
Coagulopathy
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.9%
1/17 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Cardiac disorders
Arrhythmia
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Cardiac disorders
Atrial fibrillation
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.9%
1/17 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Cardiac disorders
Cardiac arrest
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
10.5%
2/19 • Number of events 2 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Cardiac disorders
Cardiac failure congestive
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.9%
1/17 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Cardiac disorders
Cardiogenic shock
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Cardiac disorders
Cardiopulmonary failure
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.9%
1/17 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Cardiac disorders
Myocardial infarction
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.9%
1/17 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Cardiac disorders
Pericardial effusion
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.9%
1/17 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Gastrointestinal disorders
Gastric ulcer haemorrhage
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Gastrointestinal disorders
Intestinal ischaemia
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Gastrointestinal disorders
Pancreatitis
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
General disorders
Death
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Hepatobiliary disorders
Acute hepatic failure
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.9%
1/17 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Infections and infestations
Device related sepsis
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Infections and infestations
Enterococcal infection
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Infections and infestations
Escherichia bacteraemia
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Infections and infestations
Gangrene
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Infections and infestations
Osteomyelitis bacterial
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Infections and infestations
Pneumonia
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Infections and infestations
Sepsis
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.9%
1/17 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Infections and infestations
Staphylococcal bacteraemia
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Infections and infestations
Staphylococcal infection
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Infections and infestations
Staphylococcal sepsis
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Injury, poisoning and procedural complications
Ankle fracture
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Injury, poisoning and procedural complications
Arteriovenous fistula occlusion
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
Other adverse events
| Measure |
V710 (60 mcg / 60 mcg / 60 mcg)
n=18 participants at risk
Participants in Group 1A who were vaccinated with V710 (60 mcg / 60 mcg / 60 mcg) without MAA.
|
V710 (60 mcg / 60 mcg / PBO)
n=18 participants at risk
Participants in Group 1B who were vaccinated with V710 (60 mcg / 60 mcg / PBO) without MAA.
|
V710 (60 mcg / PBO / 60 mcg)
n=19 participants at risk
Participants in Group 2A who were vaccinated with V710 (60 mcg / PBO / 60 mcg) without MAA.
|
V710 (60 mcg / PBO / PBO)
n=18 participants at risk
Participants in Group 2B who were vaccinated with V710 (60 mcg / PBO / PBO) without MAA.
|
V710 (60 mcg / 60 mcg / 60 mcg) + MAA
n=19 participants at risk
Participants in Group 3A who were vaccinated with V710 (60 mcg / 60 mcg / 60 mcg) with MAA.
|
V710 (60 mcg / 60 mcg / PBO) + MAA
n=18 participants at risk
Participants in Group 3B who were vaccinated with V710 (60 mcg / 60 mcg / PBO) with MAA.
|
V710 (60 mcg / PBO / 60 mcg) + MAA
n=19 participants at risk
Participants in Group 4A who were vaccinated with V710 (60 mcg / PBO / PBO) with MAA.
|
V710 (60 mcg / PBO / PBO) + MAA
n=18 participants at risk
Participants in Group 4B who were vaccinated with V710 (60 mcg / PBO / PBO) with MAA.
|
V710 (90 mcg / 90 mcg / 90 mcg) + MAA
n=17 participants at risk
Participants in Group 5A who were vaccinated with V710 (90 mcg / 90 mcg / 90 mcg) with MAA.
|
V710 (90 mcg / 90 mcg / PBO) + MAA
n=19 participants at risk
Participants in Group 5B who were vaccinated with V710 (90 mcg / 90 mcg / PBO) with MAA.
|
Placebo (PBO / PBO / PBO)
n=18 participants at risk
Participants in Group 6 who were vaccinated with Placebo (PBO / PBO / PBO).
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Eye disorders
Eye irritation
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
General disorders
Induration
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Eye disorders
Lacrimation increased
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Blood and lymphatic system disorders
Anaemia
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 2 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Cardiac disorders
Palpitations
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Ear and labyrinth disorders
Ear pain
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Ear and labyrinth disorders
Tinnitus
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Eye disorders
Ocular hyperaemia
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Eye disorders
Vision blurred
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Gastrointestinal disorders
Abdominal discomfort
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Gastrointestinal disorders
Abdominal pain upper
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Gastrointestinal disorders
Diarrhoea
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
10.5%
2/19 • Number of events 3 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
10.5%
2/19 • Number of events 2 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Gastrointestinal disorders
Dyspepsia
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
11.1%
2/18 • Number of events 2 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 2 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 2 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Gastrointestinal disorders
Pancreatitis
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Gastrointestinal disorders
Rectal haemorrhage
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Gastrointestinal disorders
Sensitivity of teeth
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.9%
1/17 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Gastrointestinal disorders
Toothache
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
10.5%
2/19 • Number of events 2 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
General disorders
Asthenia
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
General disorders
Chest discomfort
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.9%
1/17 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
General disorders
Chills
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
General disorders
Device malfunction
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
General disorders
Feeling hot
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
General disorders
Injection site dryness
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
General disorders
Injection site erythema
|
16.7%
3/18 • Number of events 4 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
11.1%
2/18 • Number of events 2 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
15.8%
3/19 • Number of events 3 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
16.7%
3/18 • Number of events 3 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
21.1%
4/19 • Number of events 6 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
11.8%
2/17 • Number of events 2 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
10.5%
2/19 • Number of events 4 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
11.1%
2/18 • Number of events 4 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
General disorders
Injection site haematoma
|
5.6%
1/18 • Number of events 2 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
General disorders
Injection site mass
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.9%
1/17 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
General disorders
Injection site pain
|
27.8%
5/18 • Number of events 6 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
27.8%
5/18 • Number of events 6 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
16.7%
3/18 • Number of events 4 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
42.1%
8/19 • Number of events 15 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
22.2%
4/18 • Number of events 6 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
42.1%
8/19 • Number of events 13 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
27.8%
5/18 • Number of events 5 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
29.4%
5/17 • Number of events 6 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
47.4%
9/19 • Number of events 13 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
11.1%
2/18 • Number of events 3 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
General disorders
Injection site paraesthesia
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
General disorders
Injection site pruritus
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 2 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
General disorders
Injection site swelling
|
11.1%
2/18 • Number of events 4 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
10.5%
2/19 • Number of events 2 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
22.2%
4/18 • Number of events 5 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
26.3%
5/19 • Number of events 7 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
16.7%
3/18 • Number of events 3 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
11.8%
2/17 • Number of events 2 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
15.8%
3/19 • Number of events 6 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
11.1%
2/18 • Number of events 3 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
General disorders
Injection site warmth
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
General disorders
Pain
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
General disorders
Pyrexia
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
11.1%
2/18 • Number of events 2 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
11.8%
2/17 • Number of events 2 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Infections and infestations
Abdominal abscess
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Infections and infestations
Bronchitis
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Infections and infestations
Ear infection
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Infections and infestations
Herpes zoster
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Infections and infestations
Nasopharyngitis
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Infections and infestations
Orchitis
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Infections and infestations
Pharyngitis
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Infections and infestations
Sinusitis
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Injury, poisoning and procedural complications
Arteriovenous fistula site complication
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 2 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Injury, poisoning and procedural complications
Procedural pain
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Injury, poisoning and procedural complications
Shunt thrombosis
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Investigations
Pulse absent
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Investigations
Venous pressure increased
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Metabolism and nutrition disorders
Hyperkalaemia
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.9%
1/17 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Musculoskeletal and connective tissue disorders
Arthritis
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Musculoskeletal and connective tissue disorders
Bone pain
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Musculoskeletal and connective tissue disorders
Bursitis
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Musculoskeletal and connective tissue disorders
Muscle spasms
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Musculoskeletal and connective tissue disorders
Muscle twitching
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal stiffness
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Nervous system disorders
Dizziness
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 3 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Nervous system disorders
Headache
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 2 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
11.1%
2/18 • Number of events 2 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Nervous system disorders
Lethargy
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Renal and urinary disorders
Dysuria
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.9%
1/17 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonia aspiration
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Respiratory, thoracic and mediastinal disorders
Productive cough
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Respiratory, thoracic and mediastinal disorders
Rhinorrhoea
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
10.5%
2/19 • Number of events 2 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Respiratory, thoracic and mediastinal disorders
Sneezing
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.3%
1/19 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Skin and subcutaneous tissue disorders
Hyperhidrosis
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Skin and subcutaneous tissue disorders
Skin lesion
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
|
Vascular disorders
Hypotension
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/18 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/17 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
0.00%
0/19 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
5.6%
1/18 • Number of events 1 • Day 1-14 following each vaccination for all AEs (non-serious or serious). Day 1-360 for specific serious AEs (vaccine-related, resulting in death, or involving a S. aureus infection).
The table "Serious Adverse Events" displays serious AEs reported throughout the study duration (Days 1-360). The table "Other Adverse Events" displays AEs reported Day 1-14 following any vaccination.
|
Additional Information
Senior Vice President, Global Clinical Development
Merck Sharp & Dohme Corp
Phone: 1-800-672-6372
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place